Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria PfSPZ Vaccine and Sanaria PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults

Trial Profile

Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria PfSPZ Vaccine and Sanaria PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Malaria vaccine live attenuated-Sanaria (Primary) ; Malaria vaccine live unattenuated-Sanaria (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanaria
  • Most Recent Events

    • 17 Sep 2018 Planned End Date changed from 1 Jan 2020 to 1 Jun 2020.
    • 17 Sep 2018 Planned primary completion date changed from 1 Jul 2019 to 1 Apr 2020.
    • 17 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top